Sign Up

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing under the previously announced securities purchase agreement (the "SPA") entered into on March 31, 2025 with certain accredited investors.

The company issued 3,181,145 shares of common stock and 622,134 prefunded warrants and received approximately $6.0 million in gross proceeds from the issuance of such securities. The initial closing under the SPA was on April 2, 2025, where the company issued 662,269 shares of common stock and 33,983 prefunded warrants for approximately $1.1 million in gross proceeds. A remaining subscription amount under the SPA of $190,248 for 121,255 shares of common stock has not yet been received.

"This financing strengthens our balance sheet and provides critical runway to advance our pipeline of cell therapies targeting cancers and autoimmune diseases," said Sanjeev Luther, President and CEO of Ernexa Therapeutics. "We're grateful for the continued support of our investors and remain focused on delivering meaningful innovation to patients in need."

The second closing was subject to stockholder approval, as required under applicable Nasdaq listing rules, which was obtained at the company's 2025 Annual Meeting of Stockholders held ...